Martijn B. A. Doorn

Martijn B. A. Doorn

Department Of Dermatology, Erasmus Mc University Medical Centre, Rotterdam, The Netherlands

Direct Impact

Concepts for which Martijn B A Doorn has direct influence:

palmoplantar psoriasis
lentigo maligna
surgical excision
topical omiganan
dermatological laser procedures
keloidalis nuchae
inflammatory response

External impact

Concepts related to the work of other authors for which Martijn B A Doorn has influence:

hair removal
pneumatic skin
survival rate
palmoplantar psoriasis
yag laser
biologic therapy
piroxicam gel

Prominent publications by Martijn B. A. Doorn

KOL-Index: 50 Palmoplantar psoriasis is a chronic (long term) and difficult‐to‐treat form of psoriasis that affects the palms of the hands and the soles of the feet. The disease causes reddish, scaly plaques on the palms and/or soles with or without the presence of such scales elsewhere on the body. Since palms and soles are affected, the patient can have serious issues in carrying out tasks of daily life ...
Known for
Scales Palms | Studied Trial | Secukinumab Long‐lasting | Soles Issues
KOL-Index: 25 Biological drugs such as the tumour necrosis factor inhibitors have revolutionized the treatment of psoriasis, but some have the potential to induce an unwanted immune response. This immunogenicity may be associated with low trough drug levels, reduced clinical efficacy, reduced drug survival and an increased risk for adverse events. This article presents a literature review of the evidence ...
Known for
Reduced Drug | Psoriasis Implications | Immunogenicity Biologics
KOL-Index: 25 Pain is a common side-effect of dermatological laser procedures. Non-invasive anaesthetic drugs and anaesthetic procedures can be used to provide pain relief and increase patient satisfaction and treatment efficacy. However, it remains unclear which method provides the best pain relief. The objective of this systematic review was therefore to assess the efficacy and safety of non-invasive ...
Known for
Non-Randomized Trials | Pain Skin | Drugs Anaesthetic | Methods Dermatological
KOL-Index: 24 BACKGROUND: Secukinumab has shown sustained efficacy and safety in several manifestations of psoriasis. OBJECTIVES: GESTURE investigated the long-term (2·5-year) safety and efficacy of 150 mg and 300 mg subcutaneous secukinumab in 205 patients with moderate-to-severe palmoplantar psoriasis. METHODS: GESTURE was a randomized, double-blind, placebo-controlled, multicentre, phase IIIb trial ...
Known for
Ppiga 2·5 | 116 | Post-Treatment Follow-Up | Sustained Safety
KOL-Index: 20 Imiquimod (IMQ) is often used as a topical challenge agent to provoke local skin inflammation. The objective of this study was to develop and refine a rapid, temporary, and reversible human skin inflammation model with IMQ for application in clinical drug development. A randomized, vehicle-controlled, open-label, dose-ranging study was conducted in 16 healthy male subjects. IMQ (5 mg) was ...
Known for
Model Imq | Topical Challenge Agent | Tape | 16 Male
KOL-Index: 18 Omiganan is an indolicidin analog with antimicrobial properties that could be beneficial for patients with atopic dermatitis. In this randomized, double-blind, placebo-controlled, phase II trial we explored the efficacy, pharmacodynamics, and safety of topical omiganan once daily in 36 patients with mild to moderate atomic dermatitis. Patients were randomized to apply topical omiganan 1%, ...
Known for
Moderate Atomic Dermatitis | Antimicrobial Properties | 28 Consecutive | Omiganan Mild
KOL-Index: 12 Omiganan (OMN; a synthetic cationic peptide) and imiquimod (IMQ; a TLR7 agonist) have synergistic effects on interferon responses in vitro. The objective of this study was to translate this to a human model for proof-of-concept, and to explore the potential of OMN add-on treatment for viral skin diseases. Sixteen healthy volunteers received topical IMQ, OMN, or a combination of both for up ...
Known for
Tape-Stripped Skin | Synthetic Cationic Peptide | Omn Add-On | Immune Infiltration
KOL-Index: 9
Known for
Combining Biologics

Department of Dermatology, Erasmus MC University Medical Centre, Rotterdam, The Netherlands

https://www.g2.com/products/key-opinion-leaders-kols/reviews https://www.bbb.org/us/fl/doral/profile/data-analytics/key-opinion-leaders-0633-92023858 https://www.trustpilot.com/review/keyopinionleaders.com https://www.yelp.com/biz/key-opinion-leaders-miami


© 2022 - Key Opinion Leaders -
Key Opinion Leaders, LLC ,
2025 NW 102 Avenue, Suite 111 Doral , FL   33172